C3 Glomerulonephritis with High PR3 Titer Successfully Treated with Pegcetacoplan (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0737; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Following vaccinations for encapsulated organisms, the patient was initiated on the novel C3 inhibitor pegcetacoplan (1,080 mg twice weekly), bridged briefly with mycophenolate mofetil. In our case, it is not clear whether they reflected unusual ANCA-like autoimmunity or a laboratory cross-reactivity. Pegcetacoplan is a new FDA-approved therapeutic agent that elicits fast resolution of the cardinal features of C3GN."
Acute Kidney Injury • ANCA Vasculitis • Cardiovascular • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis
|
|
Allen Kai Moseley; Ali Shueib; Juan Carlos Q. Velez; Maira Asad; Ayomide Ogundipe
|